Nektar Therapeutics [NKTR] is 84.07% higher this YTD. Is it still time to buy?

Nektar Therapeutics [NASDAQ: NKTR] gained 9.47% on the last trading session, reaching $1.04 price per share at the time. The company report on March 22, 2024 at 2:00 PM that Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.

Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: This webcast will be available for replay until April 28, 2024.

If compared to the average trading volume of 1.65M shares, NKTR reached a trading volume of 3557699 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Nektar Therapeutics [NKTR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NKTR shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NKTR stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Nektar Therapeutics shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on November 20, 2023. The new note on the price target was released on November 09, 2023, representing the official price target for Nektar Therapeutics stock. Previously, the target price had yet another drop from $1.50 to $1, while Jefferies kept a Hold rating on NKTR stock. On February 24, 2023, analysts decreased their price target for NKTR shares from 3.20 to 1.50.

The Average True Range (ATR) for Nektar Therapeutics is set at 0.08, with the Price to Sales ratio for NKTR stock in the period of the last 12 months amounting to 2.12. The Price to Book ratio for the last quarter was 1.52, with the Price to Cash per share for the same quarter was set at 1.65.

Trading performance analysis for NKTR stock

Nektar Therapeutics [NKTR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.56. With this latest performance, NKTR shares gained by 15.56% in over the last four-week period, additionally plugging by 82.49% over the last 6 months – not to mention a rise of 47.96% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKTR stock in for the last two-week period is set at 69.64, with the RSI for the last a single of trading hit 73.94, and the three-weeks RSI is set at 67.11 for Nektar Therapeutics [NKTR]. The present Moving Average for the last 50 days of trading for this stock 0.7567, while it was recorded at 0.9427 for the last single week of trading, and 0.6169 for the last 200 days.

Nektar Therapeutics [NKTR]: A deeper dive into fundamental analysis

Nektar Therapeutics’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.14 and a Current Ratio set at 6.45.

Nektar Therapeutics [NKTR]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Nektar Therapeutics posted -0.73/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -192.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NKTR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nektar Therapeutics go to -7.30%.

An analysis of Institutional ownership at Nektar Therapeutics [NKTR]

The top three institutional holders of NKTR stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in NKTR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in NKTR stock with ownership which is approximately 5.8386%.